UK markets close in 3 hours 49 minutes

Centessa Pharmaceuticals plc (CNTA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.5500-0.3400 (-6.95%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 474.91M
Enterprise value -44.47M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.97
Enterprise value/revenue N/A
Enterprise value/EBITDA 4.32

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-79.08%
S&P500 52-week change 3-7.05%
52-week high 326.9000
52-week low 34.5400
50-day moving average 38.2526
200-day moving average 312.5249

Share statistics

Avg vol (3-month) 3165.3k
Avg vol (10-day) 3256.35k
Shares outstanding 594.04M
Implied shares outstanding 6N/A
Float 840.9M
% held by insiders 11.22%
% held by institutions 179.68%
Shares short (28 Apr 2022) 43.53M
Short ratio (28 Apr 2022) 422.32
Short % of float (28 Apr 2022) 4N/A
Short % of shares outstanding (28 Apr 2022) 43.76%
Shares short (prior month 30 Mar 2022) 43.43M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-24.10%
Return on equity (ttm)-51.89%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -173.99M
Net income avi to common (ttm)-196.88M
Diluted EPS (ttm)-2.2950
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)544.47M
Total cash per share (mrq)5.79
Total debt (mrq)74.8M
Total debt/equity (mrq)15.58
Current ratio (mrq)21.37
Book value per share (mrq)5.11

Cash flow statement

Operating cash flow (ttm)-173.49M
Levered free cash flow (ttm)-107.5M